IngredientesThe term taraxacin appears in the scientific and herbal literature with two related but technically distinct meanings, and understanding this duality is essential for interpreting any reference to the compound.
Meaning 1 — A specific isolated guaianolide. In the formal phytochemical sense, taraxacin refers to a discrete molecular entity: a new guaianolide, taraxacin (compound 1), and a known sesquiterpene ketolactone (compound 2), isolated from an ethyl acetate-soluble part of a methanolic extract of Taraxacum wallichii. The structure of compound 1 was established using NMR, MS, and X-ray crystallographic methods. This isolation and formal structural elucidation was reported by V.U. Ahmad and colleagues at the H.E.J. Research Institute of Chemistry, University of Karachi, published in Journal of Natural Products in July 2000 (vol. 63, no. 7, pp. 1010–1011, DOI: 10.1021/np990495+). As a guaianolide, taraxacin belongs to the sesquiterpene lactone class, a structural category characterised by a five-membered lactone ring fused to a seven-membered carbocyclic ring.
Meaning 2 — A collective bitter principle. In older herbal pharmacy and in many contemporary herbalism texts, "taraxacin" is used more loosely to denote the chief constituent of dandelion root: a crystalline bitter substance, of which the yield varies in roots collected at different seasons. This older usage predates precise structural chemistry and effectively referred to whatever bitter sesquiterpene fraction could be extracted from dandelion root. Historically, the name "taraxacin" has referred to bitter sesquiterpene lactone principles in dandelion more broadly. Modern phytochemical reviews recognise that what was once called "taraxacin" in older pharmacognosy encompasses a family of related sesquiterpene lactone glycosides rather than a single compound.
Taraxacin (in its formal phytochemical sense) is a guaianolide sesquiterpene lactone isolated from Taraxacum wallichii, a species in the genus Taraxacum within the Asteraceae family. The broader genus from which related bitter principles are derived is Taraxacum, most prominently represented by Taraxacum officinale (F.H. Wiggers) — the common dandelion. Dandelion (Taraxacum genus), named "Pugongying" in China, is a perennial plant belonging to the Asteraceae family. It has a complex classification, comprising over three hundred species, and in Asia, the Taraxacum genus is widely cultivated and found wild in most parts of China, North Korea, Mongolia, and Russia. It grows in temperate regions globally, including on lawns, on roadsides, on disturbed banks and shores of waterways, and in other areas with moist soils.
Taraxacin and related sesquiterpene lactones are recoverable from multiple plant organs, though concentrations vary by part and season. Currently, all its parts (roots, foliage, and flowers) are commercially available in different pharmacological and supplemental preparations suggested to treat, for example, some liver, gallbladder, and kidney disorders. Common preparations include:
The root contains no starch, but early in the year contains much uncrystallizable sugar and laevulin, which differs from inulin in being soluble in cold water. This diminishes in quantity during the summer and becomes inulin in the autumn. This seasonal variation is directly relevant to the yield of taraxacin and related bitter compounds, which are also known to fluctuate across the growing calendar.
Medicinal use of dandelion was first recorded in writing in the Tang Materia Medica (659 BCE), and then later noted by Arab physicians in the 10th century. In Traditional Chinese Medicine, Taraxacum officinale is known as Pu Gong Ying and is valued for clearing heat, resolving toxicity, and eliminating dampness to reduce edema and water retention via its diuretic properties. Some species have been widely used in both complementary and alternative medicine to clear heat, detoxify, activate blood circulation, dispel stasis, and discharge urine. Species of Taraxacum have been employed as a diuretic for over 2,000 years in both Traditional Chinese Medicine and in Ayurvedic medicine. Taraxacum mongolicum is a famous traditional Chinese medicine derived from the Taraxacum genus used for the treatment of inflammatory disorders and viral infectious diseases.
The Taraxacum genus as a drug was first used to treat liver and spleen diseases in Arabian medicine. Arabian physicians used the plant in medicine in the tenth and eleventh centuries. In European herbalism, Taraxacum officinale, a historical source of bitter principles once termed taraxacin, has been employed since medieval times for liver cleansing and diuretic purposes, with roots prepared as teas to alleviate hepatic disorders and promote urination.
The 12th-century abbess Hildegard von Bingen documented its use in her Physica for treating jaundice, stomach fevers, and digestive complaints, recommending infusions to support liver function and detoxification. By the 16th century, herbalists like Leonhart Fuchs expanded on these applications, prescribing dandelion preparations for gout, spleen issues, and urinary retention, often as decoctions or fresh leaf poultices. In the 16th century, the German botanist Fuchs discovered that Taraxacum can be used to treat gout, diarrhea, blisters, and spleen and liver diseases.
In the traditional societies of Central-Eastern Europe, dandelion is a source of food and medicinal raw materials. The variety of ways to prepare the raw material is noteworthy; fresh and dried raw materials were used to make extracts, tinctures, decoctions, infusions, wrap compresses, and syrups. Even before publication in Elizabeth Blackwell's Curious Herbal in 1734, the use of dandelion leaf as a diuretic persisted across cultural and temporal barriers. In French, dandelion is known as pissenlit, a colorful description of its diuretic activity.
Dandelions were not originally native to North America — the yellow flowers were brought over from Europe in the 1600s. They spread across the continent rapidly, reaching the West Coast long before the Europeans themselves, and became well-known by many tribes as a food item and medicine herb. In the United States, various Native American tribes considered dandelion to be a prized edible, a gastrointestinal aid, a cleansing alterative, and a helpful healing poultice or compress. The Bella Coola from Canada made a decoction of the roots to assuage stomach pain; the Algonquian ate the leaves for their alterative properties.
The therapeutic use of dandelion has been mentioned by Arabian, Native American, Chinese, and Ayurvedic medicine. For centuries, the Chinese and Indians have grown the dandelion to treat liver diseases and digestive problems. Across these traditions, the consistent themes associated with the root's bitter constituents — including what was collectively called taraxacin — were support of digestion, stimulation of bile production, and promotion of urination.
The chemical constituents of dandelion plants are primarily composed of sesquiterpene lactones, phenolic acids, triterpenoids, polysaccharides, phytosterols, volatile oils, and other compounds. The Taraxacum genus is abundant in sesquiterpenoids and their lactones, including α-pinene lactones, guaiacol lactones, and patchoulene lactones with their derivatives. The more abundant components are germacrane, eudesmane, and guaiane type sesquiterpene lactones.
The bitter taste of dandelion is mainly imparted by sesquiterpenoids. The only known sesquiterpene lactone components in T. officinale are two germacranolides, namely, taraxinic acid and the β-glucopyranosyl ester and its 11,13-dihydroderivative and two eudesmanolides (4a(15),11β(13)-tetrahydroridentin B, and taraxacolide-1-O-β-glucopyranoside).
Among the most important compounds in dandelion are sesquiterpene lactones (believed to have anti-inflammatory and anticancer effects), phenylpropanoids (believed to have inflammation-modulating effects). Major sesquiterpene lactones, generally occurring as glycosides, include taraxacosides, taraxacolides, dihydrolactucin, ixerin, taraxinic acids, and ainslioside.
Taraxacin or taraxinic acid or lactucopicrin, lactucin, and cichorin are chief bitter principles and belong to the guaianolide class. In modern phytochemical work, common dandelion latex is dominated by three classes of secondary metabolites: phenolic inositol esters (PIEs), triterpene acetates (TritAc), and the sesquiterpene lactone taraxinic acid β-D-glucopyranosyl ester (TA-G).
Formally, a new guaianolide, taraxacin (1), and a known sesquiterpene ketolactone (2) have been isolated from an ethyl acetate-soluble part of a methanolic extract of Taraxacum wallichii. The structure of compound 1 was established using NMR, MS, and X-ray crystallographic methods. The 13C NMR data of compound 2 is also being reported for the first time. Guaianolides are bicyclic sesquiterpene lactones sharing a five-seven ring system; the guaiane skeleton is one of the three principal sesquiterpenoid skeletal types identified in dandelion, alongside germacrane and eudesmane types.
Roots of some Taraxacum species are reported to have a hepatoprotective effect and are used against visceral diseases. No prior phytochemical work on T. wallichii had been reported before this 2000 isolation study.
Taraxacin and related sesquiterpene lactones do not exist in isolation within the whole plant — they are part of a broader phytochemical matrix that includes:
Triterpene sterols in the root bear a close structural similarity to cholesterol, which may in part explain the ability to increase the solubility of bile.
Sesquiterpene lactones (also referred to as taraxacin) create an osmotic diuretic effect and are unique to the plant (mostly in leaf). They also contribute to the bitter compounds that help stimulate digestive secretions and peristalsis, and may help improve fat (including cholesterol) metabolism in the liver. The classic mechanism by which bitter compounds like taraxacin exert this effect is through activation of bitter taste receptors (TAS2R family) on the tongue and gastrointestinal mucosa, triggering a reflex increase in salivary, gastric acid, and digestive enzyme secretion — a process long recognised in traditional pharmacognosy and consistent with dandelion's historical classification as a bitter tonic.
Dandelion, particularly its root, has been classified as a cholagogue in traditional herbal medicine, meaning it supports the production and flow of bile from the liver and gallbladder. The anti-inflammatory effects of dandelion, the prebiotic effects of its oligofructans, inhibitory effects against the release of lipopolysaccharides and fasting-induced adipose factor, digestive enzymes, and enhancing effects of lipogenesis reduce lipid accumulation and liver inflammation, which directly or indirectly improve liver functions.
In vivo evidence from paw edema assays in rodents treated with dandelion extracts rich in such lactones shows reduced edema and lowered levels of markers like TNF-α and IL-6. Among the most relevant and predominant bioactive compounds of T. officinale is taraxasterol, which modulates inflammatory and oxidative stress pathways, helping to prevent liver damage. Additionally, polysaccharides and inulin (mostly in root) activate complement, thus contributing to anti-inflammatory and immune-enhancing properties (extracts induce nitric oxide synthase in macrophages).
Dandelions contain a wide range of bioactive compounds, such as polyphenols, phytosterols, flavonoids, carotenoids, terpene, and coumarins, whose biological activities are actively explored in various areas of human health, some constituents having synergistic activities, including antioxidant, antimicrobial, anti-inflammatory, and anticancer activities. The antioxidant activity is attributed to free radical scavenging by phenolic constituents. Caftaric acid and caffeic acid could be the potential antioxidant ingredients of Taraxacum mongolicum.
The aqueous extract of shade-dried T. officinale leaves comparatively demonstrated potent antidiabetic activity under in vitro conditions in a dose-dependent manner via targeting α-amylase and α-glucosidase, the two potent enzymes of carbohydrate metabolism. The anti-diabetic properties of dandelion are attributed to bioactive chemical components including chicoric acid, taraxasterol (TS), chlorogenic acid, and sesquiterpene lactones.
Currently available pharmacological studies indicate that dandelion extracts have hepatoprotective effects against chemical agents due to their antioxidant and anti-inflammatory activities. Preclinical studies have reported that extracts of this plant protect against liver damage induced by toxic agents such as alcohol, carbon tetrachloride, and paracetamol.
Evidence strength: Preliminary human clinical evidence (one small pilot study); further replication needed.
Taraxacum officinale has been extensively employed as a diuretic in traditional folk medicine and in modern phytotherapy in Europe, Asia, and the Americas without prior clinical trial substantiation — until a pilot human study was published. In this pilot study, a high-quality fresh leaf hydroethanolic extract of the medicinal plant T. officinale (dandelion) was ingested by volunteers to investigate whether an increased urinary frequency and volume would result.
Study details: Baseline values for urinary frequency and excretion ratio (urination volume:fluid intake) were established 2 days prior to dandelion dosing (8 mL TID) and monitored throughout a 1-day dosing period and 24 hours postdosing. For the entire population (n = 17) there was a significant (p < 0.05) increase in the frequency of urination in the 5-hour period after the first dose. Ingestion of T. officinale ethanolic extract significantly increases urinary frequency (p < 0.05). The excretion ratio also rises significantly (p < 0.001) after administration. Participants (n = 17) showed a mean age of 37.9 years in a 4-day study. No adverse events were recorded, highlighting the extract's safety.
Based on these first human data, T. officinale ethanolic extract shows promise as a diuretic in humans and further studies are needed to establish the value of this herb for induction of diuresis in human subjects. This study was unblinded and lacked a placebo arm, which substantially limits conclusions; it remains the principal human clinical evidence for diuretic activity. Leaves are high in potassium, replacing potassium lost in diuresis, thus exerting a potassium-sparing effect.
Evidence strength: Preclinical (animal and in vitro) only; no adequate human clinical trials.
Historically, dandelion has been used to treat various conditions, particularly liver disorders, owing to its antioxidant and anti-inflammatory activities. Currently, there are limited clinical studies on hepatoprotective effects. Reviews evaluate the hepatoprotective effects of dandelion and its mechanism of action. Evidence for liver support remains limited, with most studies confined to animal models showing hepatoprotective benefits against toxin-induced damage, and human trials are scarce.
Dandelion has been tested against various drugs and chemically-induced chronic liver diseases in experimental animals and came out with promising results. In vitro studies also confirm the hepatoprotective, antioxidant, and anti-inflammatory properties of dandelion. Specifically, preclinical studies have reported that extracts of this plant protect against liver damage induced by toxic agents such as alcohol, carbon tetrachloride, and paracetamol. Determining the optimal dosing, evaluating its potential as an adjuvant in pharmacological treatments, as well as evaluating possible interactions with conventional drugs, is necessary for the potential use of T. officinale as an adjuvant agent in the treatment of liver diseases.
Evidence strength: In vitro and rodent studies only; no controlled human trials.
Anti-inflammatory effects have been observed in vitro and in rodent studies, but robust clinical data is lacking. Multiple pharmacological studies have highlighted therapeutic potential including anti-bacterial, anti-oxidant, anti-cancer, and anti-rheumatic activities. The mechanisms proposed involve inhibition of pro-inflammatory cytokines such as TNF-α and IL-6, observed in animal edema models.
Evidence strength: Predominantly in vitro; animal evidence; one small human-relevant clinical study with limited findings.
The study revealed the presence of medicinally important antidiabetic flavonoid quercetin present in T. officinale leaves. The aqueous extract of shade-dried T. officinale leaves demonstrated potent antidiabetic activity under in vitro conditions in a dose-dependent manner via targeting α-amylase and α-glucosidase. In addition to being a nutritious herb, the shade-dried leaves of T. officinale have great potential to suppress post-prandial glucose rise and can be better exploited through clinical trials to be used as a dietary intervention for better management of diabetes.
The result of a systematic review showed that among 20 animal and human studies, only one diabetic rat study exhibited the hypoglycemic effects of dandelion. In another study, the anti-diabetic effect of 5 g dandelion leaf or root powder for 9 days was compared with placebo on sixty type 2 diabetic patients. Overall evidence in humans remains extremely limited and inadequate to draw clinical conclusions.
Evidence strength: In vitro and ex vivo; not established in clinical trials.
A common use is as an antioxidant, due to its free radical scavenging activity. The new flavonoid hesperetin-5′-O-β-rhamnoglucoside identified from dandelion has outstanding antioxidant activity, as shown by its IC50 value (8.72 mg/L) for scavenging DPPH free radicals. These data are derived from laboratory assay systems, not human clinical endpoints.
Evidence strength: In vitro and network pharmacology only; no human clinical evidence.
Triterpenoid taraxasterol has exhibited powerful inhibitory effects on Herpes Simplex, Epstein-Barr early antigen, and experimental mammary tumours. In vitro cell-based assays and scanning electron microscopy analysis were used to validate the anti-lung cancer activity of taraxasterol, a representative sterol compound derived from dandelion. Critical translational barriers, including standardization of extracts, potential interactions with anticancer drugs (notably tyrosine kinase inhibitors), and the need for rigorous toxicity and human pharmacology studies, are discussed. Experts caution against premature clinical use without controlled trials.
Evidence strength: In vitro only.
The main sesquiterpene compounds in dandelion are sesquiterpene lactones, usually in the form of glycosides, which have anti-inflammatory and anti-bacterial activities. Antimicrobial evidence remains confined to laboratory culture systems and has not been translated into clinical studies.
Twelve therapeutic properties have been identified and described in published studies: diuretic, hepatoprotective, anticolitis, immunoprotective, antiviral, antifungal, antibacterial, antiarthritic, antidiabetic, antiobesity, antioxidant, and anticancer effects. The principal body systems with which taraxacin-containing dandelion preparations are associated include:
The following dosages appear specifically in the cited scientific or institutional sources and are presented as reported, without endorsement as therapeutic recommendations:
Regulatory assessments classify dandelion root extracts, including those with sesquiterpene lactones, as Generally Recognized as Safe (GRAS) for food use by the FDA. Toxicological data on purified taraxacin remain limited, warranting caution for its isolated use.
If you have a bile duct obstruction, gallstones, or another serious gallbladder condition, increased bile flow can cause intense pain or dangerous complications. Germany's Commission E specifically recommends against dandelion use by anyone with bile duct obstruction.
There are theoretical reasons to suspect that dandelion might interact with antidiabetes, anticoagulant, antiplatelet, and water pill drugs, among others. Specific interactions documented in the pharmacological literature include:
Dandelion belongs to the Asteraceae (Compositae) family, which includes ragweed, chrysanthemums, marigolds, and daisies. Individuals with known allergies to Asteraceae family plants may experience cross-reactive hypersensitivity reactions to dandelion preparations containing sesquiterpene lactones such as taraxacin.
Little is known about whether it's safe to use dandelion in amounts greater than those found in foods during pregnancy or while breastfeeding. No clinical data exist on whether dandelion's pharmacologically active compounds pass into breast milk, or on the safety of supplemental doses during pregnancy.
The Society for Perioperative Assessment and Quality Improvement specifically lists dandelion among herbal supplements that increase bleeding risk and recommends holding it for 2 weeks preoperatively.
Dandelion might reduce how much oxalate is released through urine. In theory, this might increase the risk for complications in people with kidney problems.
Taraxacin — whether understood as the specific guaianolide isolated from T. wallichii or as the collective bitter sesquiterpene lactone principle of dandelion — has a robust ethnopharmacological history spanning millennia across multiple major medical traditions. The compound class is well-characterised chemically, and multiple plausible biological mechanisms have been identified in laboratory and animal models. However, the clinical evidence base in humans is narrow. The diuretic effect of dandelion leaf extract is the best-supported application in humans, demonstrated in a single small (n=17), uncontrolled pilot study. Hepatoprotective, antidiabetic, anti-inflammatory, and anticancer activities, while supported by compelling in vitro and animal data, have not been rigorously established in human clinical trials. Isolated, purified taraxacin as a standalone supplement remains even less studied than whole dandelion extracts; toxicological data on the pure compound are limited. Regulatory GRAS status applies to dandelion as a food ingredient, not to isolated sesquiterpene lactone fractions at pharmacological doses.
Condiciones de salud que Taraxacina puede ayudar a apoyar.
Taraxacin is one of the principal bitter sesquiterpene lactones in Dandelion root (Taraxacum officinale), specifically identified as a key active constituent responsible for its choleretic and cholagogue effects on the liver-gallbladder axis. Sacred Plant Co's gallbladder herb review (October 2024), citing peer-reviewed research, identifies taraxacin as a bile-stimulating compound in dandelion. It appears in gallbladder compound databases as a recognized biliary-supportive constituent.
Taraxacin is the primary bitter sesquiterpene lactone in dandelion (Taraxacum officinale) responsible for its traditional cholagogue and choleretic activity. It stimulates bile production and flow via gastrointestinal bitter receptors and is the key active constituent in Commission E-approved dandelion preparations for biliary complaints.
Sistemas corporales que Taraxacina puede ayudar a apoyar.
Volver